Literature DB >> 29270739

Inhibition of HBV replication by delivering the dual-gene expression vector pHsa-miR16-siRNA in HepG2.2.15 cells.

Wei Wei1, Su-Fei Wang1, Bing Yu1, Ming Ni2.   

Abstract

This study aimed to construct the dual-gene expression vector pHsa-miR16-siRNA which can express human miR-16 and HBV X siRNA, and examine its regulatory effect on HBV gene expression in the HepG2.2.15 cell line. The expression vectors siR-1583 and pHsa-miR16-siRNA were designed and constructed. HepG2.2.15 cells were transfected with the empty vector, siR-1583, pmiR-16 and pHsa-miR16-siRNA, respectively. ELISA was performed to measure the expression of HBsAg and HBeAg in the culture supernatant 48 and72 h post transfection. Fluorescence quantitative PCR was used to measure the HBV mRNA degradation efficiency and HBV DNA copy number. The results showed that the expression of HBV genes was significantly inhibited in HepG2.2.15 cells transfected with siR-1583, pmiR-16 and pHsa-miR16-siRNA, respectively, when compared with that in cells transfected with the empty vectors, with the inhibitory effect of pHsa-miR16-siRNA being the most significant. ELISA showed that the inhibitory rates of HBsAg and HBeAg in pHsa-miR16-siRNA transfected cells were correspondingly 87.3% and 85.0% at 48 h, and 88.6% and 86.5% at 72 h post transfection (P<0.01 vs. control group). RT-PCR showed that the level of HBV mRNA decreased by 80.2% (t=-99.22, P<0.01), the genomic HBV DNA by 92.8% (t=-73.06, P<0.01), and the supernatant of HBV DNA copy number by 89.8% (t=-47.13, P<0.01) in pHsa-miR16-siRNA transfected group. It was suggested that the dual-gene expression vector pHsa-miR16-siRNA can inhibit the replication of HBV more efficiently than a single-gene expression vector.

Entities:  

Keywords:  HBV DNA; HBV mRNA; dual expression vector; gene expression

Mesh:

Substances:

Year:  2017        PMID: 29270739     DOI: 10.1007/s11596-017-1810-0

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  15 in total

Review 1.  Selection of chronic hepatitis B therapy with high barrier to resistance.

Authors:  Robert Gish; Ji-Dong Jia; Stephen Locarnini; Fabien Zoulim
Journal:  Lancet Infect Dis       Date:  2012-02-09       Impact factor: 25.071

Review 2.  Silence of the transcripts: RNA interference in medicine.

Authors:  Sailen Barik
Journal:  J Mol Med (Berl)       Date:  2005-07-19       Impact factor: 4.599

Review 3.  The role of microRNAs in hepatocyte metabolism and hepatitis B virus replication.

Authors:  Wanyu Deng; Mengji Lu
Journal:  Virol Sin       Date:  2016-12-28       Impact factor: 4.327

4.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

Authors:  David V Morrissey; Jennifer A Lockridge; Lucinda Shaw; Karin Blanchard; Kristi Jensen; Wendy Breen; Kimberly Hartsough; Lynn Machemer; Susan Radka; Vasant Jadhav; Narendra Vaish; Shawn Zinnen; Chandra Vargeese; Keith Bowman; Chris S Shaffer; Lloyd B Jeffs; Adam Judge; Ian MacLachlan; Barry Polisky
Journal:  Nat Biotechnol       Date:  2005-07-24       Impact factor: 54.908

Review 5.  siRNA-nanoparticle conjugate in gene silencing: A future cure to deadly diseases?

Authors:  Rituparna Acharya; Suman Saha; Sayantan Ray; Sugata Hazra; Manoj K Mitra; Jui Chakraborty
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2017-03-02       Impact factor: 7.328

6.  Hepatitis B virus X protein increases microRNA‑21 expression and accelerates the development of hepatoma via the phosphatase and tensin homolog/phosphoinositide 3‑kinase/protein kinase B signaling pathway.

Authors:  Zhouhua Hou; Jun Quan
Journal:  Mol Med Rep       Date:  2017-03-23       Impact factor: 2.952

7.  Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs.

Authors:  Sergio Carmona; Abdullah Ely; Carol Crowther; Naazneen Moolla; Felix H Salazar; Patricia L Marion; Nicolas Ferry; Marc S Weinberg; Patrick Arbuthnot
Journal:  Mol Ther       Date:  2005-12-05       Impact factor: 11.454

8.  Targeted inhibition of HBV gene expression by single-chain antibody mediated small interfering RNA delivery.

Authors:  Wei-Hong Wen; Jia-Yun Liu; Wei-Jun Qin; Jing Zhao; Tao Wang; Lin-Tao Jia; Yan-Ling Meng; Hui Gao; Cai-Fang Xue; Bo-Quan Jin; Li-Bo Yao; Si-Yi Chen; An-Gang Yang
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425

Review 9.  Hepatitis B virus X protein accelerates the development of hepatoma.

Authors:  Xiao-Dong Zhang; Yuan Wang; Li-Hong Ye
Journal:  Cancer Biol Med       Date:  2014-09       Impact factor: 4.248

Review 10.  Achieving HIV-1 Control through RNA-Directed Gene Regulation.

Authors:  Vera Klemm; Jye Mitchell; Christina Cortez-Jugo; Francesca Cavalieri; Geoff Symonds; Frank Caruso; Anthony Dominic Kelleher; Chantelle Ahlenstiel
Journal:  Genes (Basel)       Date:  2016-12-07       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.